Avances en el tratamiento de la leucemia linfocítica crónica / Advances in the treatment of chronic lymphocytic leukaemia
Med. clín (Ed. impr.)
; 147(10): 447-454, nov. 2016. tab, ilus, graf
Article
in Spanish
| IBECS
| ID: ibc-157776
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
La leucemia linfocítica crónica (LLC) es una proliferación de linfocitos B maduros que constituye una de las neoplasias hematológicas más prevalentes. Su tratamiento ha evolucionado en las últimas décadas hasta considerarse la inmunoquimioterapia a base de fludarabina, ciclofosfamida y rituximab el tratamiento de elección en pacientes de riesgo estándar y con buena situación funcional. Sin embargo, la caracterización de subgrupos biológicos de alto riesgo y la presentación de esta enfermedad en pacientes de edad avanzada y/o con comorbilidad ha llevado en los últimos años al desarrollo y aprobación de tratamientos dirigidos, especialmente los inhibidores del receptor del linfocito B. La presente revisión repasa las estrategias terapéuticas convencionales y se centra en las nuevas moléculas que ya constituyen elementos prometedores del actual panorama terapéutico de la LLC (AU)
ABSTRACT
Chronic lymphocytic leukemia (CLL), a proliferation of mature B cells, is one of the most prevalent haematological malignancies. Progress has been made in its treatment during the last few decades, and chemoimmunotherapy based on fludarabine, cyclophosphamide and rituximab is considered the treatment of choice for patients with standard-risk CLL and good performance status. However, due to the characterization of high-risk biological subgroups and its presentation in elderly patients and/or with comorbidities, targeted therapies, such as B-cell receptor inhibitors, have been developed and approved during the last few years. The current review examines traditional therapeutic strategies and focuses on new small molecules that already represent promising elements of the CLL treatment landscape (AU)
Search on Google
Collection:
National databases
/
Spain
Health context:
Sustainable Health Agenda for the Americas
/
SDG3 - Health and Well-Being
Health problem:
Goal 9: Noncommunicable diseases and mental health
/
Target 3.4: Reduce premature mortality due to noncommunicable diseases
Database:
IBECS
Main subject:
Receptors, Antigen, B-Cell
/
Leukemia, Lymphocytic, Chronic, B-Cell
/
Cyclophosphamide
/
Alkylating Agents
/
Rituximab
/
Immunotherapy
Limits:
Female
/
Humans
/
Male
Language:
Spanish
Journal:
Med. clín (Ed. impr.)
Year:
2016
Document type:
Article
Institution/Affiliation country:
Hospital Clínic/España